Previous 10 | Next 10 |
2023-12-06 07:40:06 ET More on Coya Therapeutics Historical earnings data for Coya Therapeutics Financial information for Coya Therapeutics For further details see: Dr Reddy's licenses Coya ALS candidate in exclusive deal
Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will be responsible for development, including the conduct of the Phase 2 clinical trial and fo...
2023-12-01 13:40:47 ET More on Amarin, Amneal, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript ...
2023-11-29 01:15:52 ET Summary Dr. Reddy's Laboratories reports impressive financial results, with record-breaking sales and profitability in their recent quarter. The company shows strong growth in their India, North America, Europe, and Emerging Markets businesses. Dr. Reddy...
2023-11-16 15:00:31 ET More on Dr. Reddy's Dr Reddy's Laboratories Ltd (RDY) Q2 2024 Earnings Call Transcript Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook Dr. Reddy's: Growth Supported By New Labels, Profitability Seeking A...
2023-10-27 14:48:06 ET Dr Reddy’s Laboratories Ltd (RDY) Q2 2024 Earnings Conference Call October 27, 2023, 10:00 ET Company Participants Richa Periwal - IR Parag Agarwal - CFO Erez Israeli - CEO Conference Call Participants Mikaela Franceschin...
2023-10-27 14:23:03 ET Summary Generic pharmaceutical manufacturers could benefit from structural tailwinds and are attractive in the current market environment. Dr. Reddy's Laboratories Limited (RDY) has posted impressionable Q2 fiscal '24 results, supporting a long-term investme...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended Sep 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Finan...
2023-10-27 07:21:46 ET Dr. Reddy's: Growth Supported By New Labels, Profitability Dr. Reddy's launches generic version of Kombiglyze XR in US Seeking Alpha’s Quant Rating on Dr. Reddy's Historical earnings data for Dr. Reddy's For further details s...
FNCB Bancorp Inc. (FNCB) is expected to report for Q1 2024 Civista Bancshares Inc. (CIVB) is expected to report $0.6 for Q3 2023 ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023 Grupo Televisa S.A. (TV) is expected to report $0.02 for Q3 2023 Red River...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of...
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product Alvotech (NASDAQ: ALVO), a global biotech compa...